Iclepertin
- Generic Name
- Iclepertin
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 620
- Registration Number
- NCT04846868
- Locations
- π§π·
Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil
π§π·BR Trials, Sao Paulo, Brazil
π¬π·University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT04602221
- Locations
- πΊπΈ
Hassman Research Institute, Marlton, New Jersey, United States
πΊπΈCollaborative Neuroscience Research, LLC, Long Beach, California, United States
A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03988803
- Locations
- π©πͺ
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT03905096
- Locations
- π©πͺ
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 200
- Registration Number
- NCT03859973
- Locations
- π¨π¦
Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
π«π·HOP Saint-Jacques, Nantes, France
πΊπΈCenter for Behavioral Medicine, Kansas City, Missouri, United States
A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet
- Conditions
- Healthy
- Interventions
- Drug: BI 425809 mixed with [C-14]-BI 425809
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT03783000
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
DDI Strong CYP3A4 Inducer
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03082183
- Locations
- π©πͺ
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02783040
- Locations
- π©πͺ
1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02383888
- Locations
- π°π·
1346.4.82001 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of
Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809
- First Posted Date
- 2015-02-13
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02362516
- Locations
- π§πͺ
1346.3.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.